nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Dactinomycin—sarcoma	0.142	0.24	CbGbCtD
Leflunomide—ABCG2—Mitoxantrone—sarcoma	0.127	0.215	CbGbCtD
Leflunomide—ABCG2—Vincristine—sarcoma	0.0873	0.148	CbGbCtD
Leflunomide—ABCG2—Etoposide—sarcoma	0.08	0.135	CbGbCtD
Leflunomide—CYP1A2—Dacarbazine—sarcoma	0.0674	0.114	CbGbCtD
Leflunomide—ABCG2—Doxorubicin—sarcoma	0.0546	0.0923	CbGbCtD
Leflunomide—CYP1A2—Etoposide—sarcoma	0.033	0.0558	CbGbCtD
Leflunomide—DHODH—myometrium—sarcoma	0.00572	0.0682	CbGeAlD
Leflunomide—DHODH—hematopoietic system—sarcoma	0.00492	0.0586	CbGeAlD
Leflunomide—DHODH—skin of body—sarcoma	0.00427	0.0509	CbGeAlD
Leflunomide—DHODH—cardiac atrium—sarcoma	0.00373	0.0445	CbGeAlD
Leflunomide—PTK2B—embryo—sarcoma	0.00349	0.0416	CbGeAlD
Leflunomide—DHODH—lymphoid tissue—sarcoma	0.00346	0.0412	CbGeAlD
Leflunomide—DHODH—tendon—sarcoma	0.00325	0.0388	CbGeAlD
Leflunomide—PTK2B—hematopoietic system—sarcoma	0.00311	0.0371	CbGeAlD
Leflunomide—PTK2B—connective tissue—sarcoma	0.003	0.0357	CbGeAlD
Leflunomide—AHR—myometrium—sarcoma	0.00298	0.0355	CbGeAlD
Leflunomide—PTK2B—smooth muscle tissue—sarcoma	0.00274	0.0327	CbGeAlD
Leflunomide—DHODH—testis—sarcoma	0.00269	0.0321	CbGeAlD
Leflunomide—AHR—seminal vesicle—sarcoma	0.00269	0.0321	CbGeAlD
Leflunomide—DHODH—liver—sarcoma	0.00255	0.0303	CbGeAlD
Leflunomide—AHR—smooth muscle tissue—sarcoma	0.00225	0.0269	CbGeAlD
Leflunomide—PTK2B—lymphoid tissue—sarcoma	0.00219	0.0261	CbGeAlD
Leflunomide—PTK2B—tendon—sarcoma	0.00206	0.0246	CbGeAlD
Leflunomide—PTK2B—bone marrow—sarcoma	0.002	0.0238	CbGeAlD
Leflunomide—DHODH—lymph node—sarcoma	0.00195	0.0233	CbGeAlD
Leflunomide—AHR—cardiac atrium—sarcoma	0.00194	0.0232	CbGeAlD
Leflunomide—AHR—uterus—sarcoma	0.00193	0.023	CbGeAlD
Leflunomide—PTK2B—testis—sarcoma	0.00171	0.0203	CbGeAlD
Leflunomide—AHR—tendon—sarcoma	0.00169	0.0202	CbGeAlD
Leflunomide—AHR—bone marrow—sarcoma	0.00164	0.0196	CbGeAlD
Leflunomide—PTK2B—liver—sarcoma	0.00161	0.0192	CbGeAlD
Leflunomide—PTK2B—Signal regulatory protein (SIRP) family interactions—SRC—sarcoma	0.00156	0.0176	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—PLCG1—sarcoma	0.0015	0.0169	CbGpPWpGaD
Leflunomide—CYP2C9—mammary gland—sarcoma	0.00149	0.0177	CbGeAlD
Leflunomide—AHR—testis—sarcoma	0.0014	0.0167	CbGeAlD
Leflunomide—AHR—liver—sarcoma	0.00133	0.0158	CbGeAlD
Leflunomide—PTK2B—LPA receptor mediated events—PLCG1—sarcoma	0.00131	0.0148	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—FLT1—sarcoma	0.00127	0.0143	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—PLCG1—sarcoma	0.00125	0.0141	CbGpPWpGaD
Leflunomide—PTK2B—lymph node—sarcoma	0.00124	0.0147	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.00119	0.0133	CbGpPWpGaD
Leflunomide—ABCG2—myometrium—sarcoma	0.00116	0.0138	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.00115	0.013	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—ATF1—sarcoma	0.00114	0.0129	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—MMP2—sarcoma	0.00112	0.0126	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—PTPRC—sarcoma	0.00108	0.0122	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFC—sarcoma	0.00105	0.0118	CbGpPWpGaD
Leflunomide—ABCG2—seminal vesicle—sarcoma	0.00104	0.0124	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.00103	0.0116	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.00103	0.0116	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—CCND1—sarcoma	0.00103	0.0116	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—FLT1—sarcoma	0.00103	0.0116	CbGpPWpGaD
Leflunomide—AHR—lymph node—sarcoma	0.00102	0.0121	CbGeAlD
Leflunomide—PTK2B—CXCR4-mediated signaling events—CXCR4—sarcoma	0.00101	0.0114	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.00101	0.0113	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—PLCG1—sarcoma	0.000999	0.0113	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000995	0.0112	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—IGF1R—sarcoma	0.000991	0.0112	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—FOXO1—sarcoma	0.000963	0.0108	CbGpPWpGaD
Leflunomide—CYP1A2—hematopoietic system—sarcoma	0.000956	0.0114	CbGeAlD
Leflunomide—ABCG2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000954	0.0107	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000927	0.0104	CbGpPWpGaD
Leflunomide—CYP2C9—hematopoietic system—sarcoma	0.000907	0.0108	CbGeAlD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	0.000906	0.0102	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000906	0.0102	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—PLCG1—sarcoma	0.00087	0.0098	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—JUN—sarcoma	0.000868	0.00977	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000856	0.00964	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—FOXO1—sarcoma	0.000854	0.00962	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—FLT1—sarcoma	0.000836	0.00941	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—MYC—sarcoma	0.000828	0.00933	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—PLCG1—sarcoma	0.000821	0.00925	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.00081	0.00912	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—JUN—sarcoma	0.000806	0.00908	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—KDR—sarcoma	0.00078	0.00879	CbGpPWpGaD
Leflunomide—PTK2B—Alpha-synuclein signaling—SRC—sarcoma	0.000778	0.00876	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000769	0.00866	CbGpPWpGaD
Leflunomide—ABCG2—uterus—sarcoma	0.00075	0.00894	CbGeAlD
Leflunomide—PTK2B—CXCR4-mediated signaling events—FOXO1—sarcoma	0.000749	0.00844	CbGpPWpGaD
Leflunomide—PTK2B—Alpha4 beta1 integrin signaling events—SRC—sarcoma	0.00074	0.00834	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—KDR—sarcoma	0.000734	0.00827	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000728	0.0082	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—SRC—sarcoma	0.000723	0.00814	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—IL2—sarcoma	0.0007	0.00788	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—CREB1—sarcoma	0.000698	0.00786	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—PLCG1—sarcoma	0.000686	0.00773	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—JUN—sarcoma	0.000681	0.00766	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CREB1—sarcoma	0.000667	0.00751	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—IL2—sarcoma	0.000639	0.0072	CbGpPWpGaD
Leflunomide—ABCG2—bone marrow—sarcoma	0.000637	0.00758	CbGeAlD
Leflunomide—PTK2B—LPA receptor mediated events—MMP2—sarcoma	0.000629	0.00708	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—PLCG1—sarcoma	0.000625	0.00703	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CREB1—sarcoma	0.000619	0.00698	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—KDR—sarcoma	0.000594	0.00669	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—ATF1—sarcoma	0.000593	0.00668	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—IL2—sarcoma	0.000572	0.00644	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000572	0.00644	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—JUN—sarcoma	0.000557	0.00627	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—JUN—sarcoma	0.000557	0.00627	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MYC—sarcoma	0.000547	0.00616	CbGpPWpGaD
Leflunomide—ABCG2—testis—sarcoma	0.000544	0.00648	CbGeAlD
Leflunomide—PTK2B—Interleukin-2 signaling—NRAS—sarcoma	0.000537	0.00604	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000535	0.00603	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000527	0.00593	CbGpPWpGaD
Leflunomide—ABCG2—liver—sarcoma	0.000514	0.00613	CbGeAlD
Leflunomide—PTK2B—TCR Signaling Pathway—CREB1—sarcoma	0.000514	0.00579	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MDM2—sarcoma	0.000512	0.00577	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KDR—sarcoma	0.000511	0.00575	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—HRAS—sarcoma	0.000509	0.00573	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CCND1—sarcoma	0.000506	0.0057	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CTNNB1—sarcoma	0.000501	0.00564	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—SRC—sarcoma	0.000499	0.00562	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—CTNNB1—sarcoma	0.000498	0.00561	CbGpPWpGaD
Leflunomide—CYP1A2—liver—sarcoma	0.000495	0.0059	CbGeAlD
Leflunomide—AHR—Circadian rythm related genes—CREB1—sarcoma	0.000493	0.00555	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—JUN—sarcoma	0.000492	0.00554	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—JUN—sarcoma	0.000486	0.00547	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—KDR—sarcoma	0.000482	0.00543	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—NRAS—sarcoma	0.00048	0.00541	CbGpPWpGaD
Leflunomide—CYP2C9—liver—sarcoma	0.00047	0.0056	CbGeAlD
Leflunomide—PTK2B—Interleukin-2 signaling—KRAS—sarcoma	0.000462	0.0052	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—CTNNB1—sarcoma	0.000459	0.00517	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MYC—sarcoma	0.000447	0.00504	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CCND1—sarcoma	0.000446	0.00503	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—JUN—sarcoma	0.000445	0.00502	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—FOXO1—sarcoma	0.000443	0.00499	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CTNNB1—sarcoma	0.000442	0.00498	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—SRC—sarcoma	0.000441	0.00497	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—SRC—sarcoma	0.000441	0.00497	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—SRC—sarcoma	0.000436	0.00491	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—SRC—sarcoma	0.00043	0.00485	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—VEGFA—sarcoma	0.00043	0.00484	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—HRAS—sarcoma	0.00043	0.00484	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—VEGFA—sarcoma	0.000419	0.00472	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—SRC—sarcoma	0.000415	0.00468	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—KRAS—sarcoma	0.000413	0.00466	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	0.000409	0.0046	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VEGFA—sarcoma	0.000404	0.00455	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—PLCG1—sarcoma	0.000403	0.00454	CbGpPWpGaD
Leflunomide—ABCG2—lymph node—sarcoma	0.000394	0.0047	CbGeAlD
Leflunomide—PTK2B—Interleukin-2 signaling—HRAS—sarcoma	0.000393	0.00442	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	0.000389	0.00438	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—EGFR—sarcoma	0.000382	0.0043	CbGpPWpGaD
Leflunomide—CYP2C9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000381	0.00429	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—JUN—sarcoma	0.00037	0.00417	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MYC—sarcoma	0.000358	0.00403	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—KRAS—sarcoma	0.000356	0.00401	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—JUN—sarcoma	0.000354	0.00399	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CREB1—sarcoma	0.000353	0.00398	CbGpPWpGaD
Leflunomide—CYP1A2—Melatonin metabolism and effects—FOXO1—sarcoma	0.000352	0.00396	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—HRAS—sarcoma	0.000351	0.00396	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—SRC—sarcoma	0.000351	0.00395	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EGFR—sarcoma	0.00035	0.00394	CbGpPWpGaD
Leflunomide—CYP1A2—Estrogen Receptor Pathway—JUN—sarcoma	0.000349	0.00393	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—ENO2—sarcoma	0.000345	0.00388	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—HBA1—sarcoma	0.000343	0.00386	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—KRAS—sarcoma	0.000331	0.00373	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—IL2—sarcoma	0.000329	0.0037	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—VEGFA—sarcoma	0.000327	0.00369	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—CREB1—sarcoma	0.000321	0.00362	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—CTNNB1—sarcoma	0.00032	0.0036	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—sarcoma	0.000317	0.00357	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—HRAS—sarcoma	0.000311	0.0035	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—sarcoma	0.000307	0.00345	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.000306	0.00345	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—sarcoma	0.000303	0.00341	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—CTNNB1—sarcoma	0.000302	0.0034	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—sarcoma	0.000294	0.00331	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PLCG1—sarcoma	0.000293	0.00329	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—SRC—sarcoma	0.000289	0.00325	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—VEGFA—sarcoma	0.000281	0.00317	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—NRAS—sarcoma	0.000278	0.00313	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—NRAS—sarcoma	0.000276	0.00311	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—CTNNB1—sarcoma	0.000274	0.00308	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—SRC—sarcoma	0.000273	0.00307	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—VEGFA—sarcoma	0.000266	0.00299	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—NRAS—sarcoma	0.000262	0.00295	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—JUN—sarcoma	0.000254	0.00286	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—sarcoma	0.000253	0.00285	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CTNNB1—sarcoma	0.000252	0.00284	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—SRC—sarcoma	0.000247	0.00278	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—KRAS—sarcoma	0.000239	0.00269	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—KRAS—sarcoma	0.000237	0.00267	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—sarcoma	0.000234	0.00263	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—sarcoma	0.000234	0.00263	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—JUN—sarcoma	0.000231	0.0026	CbGpPWpGaD
Leflunomide—Body temperature increased—Mitoxantrone—sarcoma	0.000229	0.000972	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Doxorubicin—sarcoma	0.000229	0.000972	CcSEcCtD
Leflunomide—Bronchitis—Epirubicin—sarcoma	0.000229	0.000969	CcSEcCtD
Leflunomide—Diarrhoea—Dactinomycin—sarcoma	0.000228	0.000967	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—SRC—sarcoma	0.000228	0.00257	CbGpPWpGaD
Leflunomide—Pancytopenia—Epirubicin—sarcoma	0.000226	0.000957	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—KRAS—sarcoma	0.000226	0.00254	CbGpPWpGaD
Leflunomide—Hypotension—Etoposide—sarcoma	0.000226	0.000955	CcSEcCtD
Leflunomide—Gastritis—Doxorubicin—sarcoma	0.000225	0.000955	CcSEcCtD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	0.000225	0.00253	CbGpPWpGaD
Leflunomide—Dysuria—Epirubicin—sarcoma	0.000223	0.000942	CcSEcCtD
Leflunomide—Neutropenia—Epirubicin—sarcoma	0.000223	0.000942	CcSEcCtD
Leflunomide—Dizziness—Thiotepa—sarcoma	0.000222	0.000941	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Epirubicin—sarcoma	0.000221	0.000937	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—JUN—sarcoma	0.00022	0.00248	CbGpPWpGaD
Leflunomide—Asthma—Doxorubicin—sarcoma	0.00022	0.000933	CcSEcCtD
Leflunomide—Influenza—Doxorubicin—sarcoma	0.00022	0.000933	CcSEcCtD
Leflunomide—Pollakiuria—Epirubicin—sarcoma	0.00022	0.000931	CcSEcCtD
Leflunomide—Hypersensitivity—Vincristine—sarcoma	0.00022	0.00093	CcSEcCtD
Leflunomide—Eosinophilia—Doxorubicin—sarcoma	0.000218	0.000923	CcSEcCtD
Leflunomide—Paraesthesia—Etoposide—sarcoma	0.000217	0.000918	CcSEcCtD
Leflunomide—Pancreatitis—Doxorubicin—sarcoma	0.000216	0.000914	CcSEcCtD
Leflunomide—Weight decreased—Epirubicin—sarcoma	0.000215	0.000912	CcSEcCtD
Leflunomide—Dyspnoea—Etoposide—sarcoma	0.000215	0.000912	CcSEcCtD
Leflunomide—Hyperglycaemia—Epirubicin—sarcoma	0.000215	0.000909	CcSEcCtD
Leflunomide—Angina pectoris—Doxorubicin—sarcoma	0.000214	0.000908	CcSEcCtD
Leflunomide—Hypersensitivity—Mitoxantrone—sarcoma	0.000214	0.000906	CcSEcCtD
Leflunomide—Asthenia—Vincristine—sarcoma	0.000214	0.000906	CcSEcCtD
Leflunomide—Vomiting—Thiotepa—sarcoma	0.000214	0.000905	CcSEcCtD
Leflunomide—Pneumonia—Epirubicin—sarcoma	0.000213	0.000904	CcSEcCtD
Leflunomide—Infestation NOS—Epirubicin—sarcoma	0.000212	0.000899	CcSEcCtD
Leflunomide—Infestation—Epirubicin—sarcoma	0.000212	0.000899	CcSEcCtD
Leflunomide—Vomiting—Dactinomycin—sarcoma	0.000212	0.000898	CcSEcCtD
Leflunomide—Rash—Thiotepa—sarcoma	0.000212	0.000897	CcSEcCtD
Leflunomide—Bronchitis—Doxorubicin—sarcoma	0.000212	0.000897	CcSEcCtD
Leflunomide—Dermatitis—Thiotepa—sarcoma	0.000212	0.000897	CcSEcCtD
Leflunomide—Headache—Thiotepa—sarcoma	0.000211	0.000892	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.00021	0.000891	CcSEcCtD
Leflunomide—Rash—Dactinomycin—sarcoma	0.00021	0.000891	CcSEcCtD
Leflunomide—Decreased appetite—Etoposide—sarcoma	0.00021	0.000889	CcSEcCtD
Leflunomide—Pancytopenia—Doxorubicin—sarcoma	0.000209	0.000886	CcSEcCtD
Leflunomide—Renal failure—Epirubicin—sarcoma	0.000209	0.000883	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Etoposide—sarcoma	0.000208	0.000883	CcSEcCtD
Leflunomide—Asthenia—Mitoxantrone—sarcoma	0.000208	0.000882	CcSEcCtD
Leflunomide—Fatigue—Etoposide—sarcoma	0.000208	0.000882	CcSEcCtD
Leflunomide—Neuropathy peripheral—Epirubicin—sarcoma	0.000208	0.000881	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—SRC—sarcoma	0.000207	0.00233	CbGpPWpGaD
Leflunomide—Jaundice—Epirubicin—sarcoma	0.000207	0.000876	CcSEcCtD
Leflunomide—Stomatitis—Epirubicin—sarcoma	0.000207	0.000876	CcSEcCtD
Leflunomide—Constipation—Etoposide—sarcoma	0.000206	0.000874	CcSEcCtD
Leflunomide—Pain—Etoposide—sarcoma	0.000206	0.000874	CcSEcCtD
Leflunomide—Urinary tract infection—Epirubicin—sarcoma	0.000206	0.000873	CcSEcCtD
Leflunomide—Conjunctivitis—Epirubicin—sarcoma	0.000206	0.000873	CcSEcCtD
Leflunomide—Dysuria—Doxorubicin—sarcoma	0.000206	0.000872	CcSEcCtD
Leflunomide—Neutropenia—Doxorubicin—sarcoma	0.000206	0.000872	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000205	0.000867	CcSEcCtD
Leflunomide—Diarrhoea—Vincristine—sarcoma	0.000204	0.000864	CcSEcCtD
Leflunomide—Pollakiuria—Doxorubicin—sarcoma	0.000203	0.000861	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—sarcoma	0.000203	0.00229	CbGpPWpGaD
Leflunomide—Haematuria—Epirubicin—sarcoma	0.000202	0.000857	CcSEcCtD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—sarcoma	0.000202	0.00227	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Epirubicin—sarcoma	0.000201	0.00085	CcSEcCtD
Leflunomide—Epistaxis—Epirubicin—sarcoma	0.0002	0.000848	CcSEcCtD
Leflunomide—Nausea—Thiotepa—sarcoma	0.0002	0.000845	CcSEcCtD
Leflunomide—Weight decreased—Doxorubicin—sarcoma	0.000199	0.000844	CcSEcCtD
Leflunomide—Sinusitis—Epirubicin—sarcoma	0.000199	0.000843	CcSEcCtD
Leflunomide—Feeling abnormal—Etoposide—sarcoma	0.000199	0.000843	CcSEcCtD
Leflunomide—Hyperglycaemia—Doxorubicin—sarcoma	0.000199	0.000841	CcSEcCtD
Leflunomide—Diarrhoea—Mitoxantrone—sarcoma	0.000199	0.000841	CcSEcCtD
Leflunomide—Nausea—Dactinomycin—sarcoma	0.000198	0.000839	CcSEcCtD
Leflunomide—Agranulocytosis—Epirubicin—sarcoma	0.000198	0.000839	CcSEcCtD
Leflunomide—Pneumonia—Doxorubicin—sarcoma	0.000197	0.000836	CcSEcCtD
Leflunomide—Gastrointestinal pain—Etoposide—sarcoma	0.000197	0.000836	CcSEcCtD
Leflunomide—Dizziness—Vincristine—sarcoma	0.000197	0.000835	CcSEcCtD
Leflunomide—Infestation NOS—Doxorubicin—sarcoma	0.000196	0.000831	CcSEcCtD
Leflunomide—Infestation—Doxorubicin—sarcoma	0.000196	0.000831	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000195	0.000824	CcSEcCtD
Leflunomide—Renal failure—Doxorubicin—sarcoma	0.000193	0.000817	CcSEcCtD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.000193	0.00217	CbGpPWpGaD
Leflunomide—Neuropathy peripheral—Doxorubicin—sarcoma	0.000192	0.000815	CcSEcCtD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—sarcoma	0.000192	0.00216	CbGpPWpGaD
Leflunomide—Urticaria—Etoposide—sarcoma	0.000192	0.000812	CcSEcCtD
Leflunomide—Haemoglobin—Epirubicin—sarcoma	0.000191	0.000811	CcSEcCtD
Leflunomide—Stomatitis—Doxorubicin—sarcoma	0.000191	0.00081	CcSEcCtD
Leflunomide—Jaundice—Doxorubicin—sarcoma	0.000191	0.00081	CcSEcCtD
Leflunomide—Rhinitis—Epirubicin—sarcoma	0.000191	0.000809	CcSEcCtD
Leflunomide—Abdominal pain—Etoposide—sarcoma	0.000191	0.000808	CcSEcCtD
Leflunomide—Body temperature increased—Etoposide—sarcoma	0.000191	0.000808	CcSEcCtD
Leflunomide—Conjunctivitis—Doxorubicin—sarcoma	0.000191	0.000808	CcSEcCtD
Leflunomide—Urinary tract infection—Doxorubicin—sarcoma	0.000191	0.000808	CcSEcCtD
Leflunomide—Haemorrhage—Epirubicin—sarcoma	0.00019	0.000807	CcSEcCtD
Leflunomide—Hepatitis—Epirubicin—sarcoma	0.00019	0.000807	CcSEcCtD
Leflunomide—Vomiting—Vincristine—sarcoma	0.000189	0.000803	CcSEcCtD
Leflunomide—Pharyngitis—Epirubicin—sarcoma	0.000189	0.000801	CcSEcCtD
Leflunomide—Urinary tract disorder—Epirubicin—sarcoma	0.000188	0.000797	CcSEcCtD
Leflunomide—Rash—Vincristine—sarcoma	0.000188	0.000796	CcSEcCtD
Leflunomide—Dermatitis—Vincristine—sarcoma	0.000188	0.000795	CcSEcCtD
Leflunomide—Oedema peripheral—Epirubicin—sarcoma	0.000188	0.000795	CcSEcCtD
Leflunomide—Haematuria—Doxorubicin—sarcoma	0.000187	0.000793	CcSEcCtD
Leflunomide—Connective tissue disorder—Epirubicin—sarcoma	0.000187	0.000793	CcSEcCtD
Leflunomide—Urethral disorder—Epirubicin—sarcoma	0.000187	0.000791	CcSEcCtD
Leflunomide—Headache—Vincristine—sarcoma	0.000187	0.000791	CcSEcCtD
Leflunomide—PTK2B—Immune System—CD34—sarcoma	0.000186	0.0021	CbGpPWpGaD
Leflunomide—Hepatobiliary disease—Doxorubicin—sarcoma	0.000186	0.000786	CcSEcCtD
Leflunomide—Epistaxis—Doxorubicin—sarcoma	0.000185	0.000784	CcSEcCtD
Leflunomide—Vomiting—Mitoxantrone—sarcoma	0.000185	0.000782	CcSEcCtD
Leflunomide—Sinusitis—Doxorubicin—sarcoma	0.000184	0.00078	CcSEcCtD
Leflunomide—Agranulocytosis—Doxorubicin—sarcoma	0.000183	0.000776	CcSEcCtD
Leflunomide—Rash—Mitoxantrone—sarcoma	0.000183	0.000775	CcSEcCtD
Leflunomide—Dermatitis—Mitoxantrone—sarcoma	0.000183	0.000774	CcSEcCtD
Leflunomide—Headache—Mitoxantrone—sarcoma	0.000182	0.00077	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—sarcoma	0.000182	0.00205	CbGpPWpGaD
Leflunomide—Erythema multiforme—Epirubicin—sarcoma	0.00018	0.000763	CcSEcCtD
Leflunomide—Eye disorder—Epirubicin—sarcoma	0.000178	0.000754	CcSEcCtD
Leflunomide—Hypersensitivity—Etoposide—sarcoma	0.000178	0.000753	CcSEcCtD
Leflunomide—Haemoglobin—Doxorubicin—sarcoma	0.000177	0.00075	CcSEcCtD
Leflunomide—Nausea—Vincristine—sarcoma	0.000177	0.00075	CcSEcCtD
Leflunomide—Cardiac disorder—Epirubicin—sarcoma	0.000177	0.000749	CcSEcCtD
Leflunomide—Rhinitis—Doxorubicin—sarcoma	0.000177	0.000748	CcSEcCtD
Leflunomide—Haemorrhage—Doxorubicin—sarcoma	0.000176	0.000746	CcSEcCtD
Leflunomide—Hepatitis—Doxorubicin—sarcoma	0.000176	0.000746	CcSEcCtD
Leflunomide—Pharyngitis—Doxorubicin—sarcoma	0.000175	0.000741	CcSEcCtD
Leflunomide—Urinary tract disorder—Doxorubicin—sarcoma	0.000174	0.000737	CcSEcCtD
Leflunomide—Oedema peripheral—Doxorubicin—sarcoma	0.000174	0.000735	CcSEcCtD
Leflunomide—Asthenia—Etoposide—sarcoma	0.000173	0.000734	CcSEcCtD
Leflunomide—Connective tissue disorder—Doxorubicin—sarcoma	0.000173	0.000734	CcSEcCtD
Leflunomide—Urethral disorder—Doxorubicin—sarcoma	0.000173	0.000732	CcSEcCtD
Leflunomide—Nausea—Mitoxantrone—sarcoma	0.000172	0.00073	CcSEcCtD
Leflunomide—Immune system disorder—Epirubicin—sarcoma	0.000172	0.000729	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—KRAS—sarcoma	0.000172	0.00193	CbGpPWpGaD
Leflunomide—Mediastinal disorder—Epirubicin—sarcoma	0.000172	0.000727	CcSEcCtD
Leflunomide—Chills—Epirubicin—sarcoma	0.000171	0.000724	CcSEcCtD
Leflunomide—Pruritus—Etoposide—sarcoma	0.000171	0.000723	CcSEcCtD
Leflunomide—Arrhythmia—Epirubicin—sarcoma	0.00017	0.000721	CcSEcCtD
Leflunomide—Alopecia—Epirubicin—sarcoma	0.000168	0.000713	CcSEcCtD
Leflunomide—Mental disorder—Epirubicin—sarcoma	0.000167	0.000707	CcSEcCtD
Leflunomide—Erythema multiforme—Doxorubicin—sarcoma	0.000167	0.000706	CcSEcCtD
Leflunomide—Malnutrition—Epirubicin—sarcoma	0.000166	0.000702	CcSEcCtD
Leflunomide—Diarrhoea—Etoposide—sarcoma	0.000165	0.0007	CcSEcCtD
Leflunomide—Eye disorder—Doxorubicin—sarcoma	0.000165	0.000698	CcSEcCtD
Leflunomide—Cardiac disorder—Doxorubicin—sarcoma	0.000164	0.000693	CcSEcCtD
Leflunomide—Flatulence—Epirubicin—sarcoma	0.000163	0.000692	CcSEcCtD
Leflunomide—Dysgeusia—Epirubicin—sarcoma	0.000162	0.000688	CcSEcCtD
Leflunomide—Back pain—Epirubicin—sarcoma	0.00016	0.000679	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—sarcoma	0.00016	0.00181	CbGpPWpGaD
Leflunomide—Dizziness—Etoposide—sarcoma	0.00016	0.000676	CcSEcCtD
Leflunomide—Muscle spasms—Epirubicin—sarcoma	0.000159	0.000675	CcSEcCtD
Leflunomide—Immune system disorder—Doxorubicin—sarcoma	0.000159	0.000674	CcSEcCtD
Leflunomide—Mediastinal disorder—Doxorubicin—sarcoma	0.000159	0.000673	CcSEcCtD
Leflunomide—Chills—Doxorubicin—sarcoma	0.000158	0.00067	CcSEcCtD
Leflunomide—Arrhythmia—Doxorubicin—sarcoma	0.000157	0.000667	CcSEcCtD
Leflunomide—Vision blurred—Epirubicin—sarcoma	0.000156	0.000662	CcSEcCtD
Leflunomide—Alopecia—Doxorubicin—sarcoma	0.000156	0.00066	CcSEcCtD
Leflunomide—Mental disorder—Doxorubicin—sarcoma	0.000154	0.000654	CcSEcCtD
Leflunomide—Ill-defined disorder—Epirubicin—sarcoma	0.000154	0.000652	CcSEcCtD
Leflunomide—Vomiting—Etoposide—sarcoma	0.000153	0.00065	CcSEcCtD
Leflunomide—Malnutrition—Doxorubicin—sarcoma	0.000153	0.00065	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—IL2—sarcoma	0.000153	0.00173	CbGpPWpGaD
Leflunomide—Anaemia—Epirubicin—sarcoma	0.000153	0.000649	CcSEcCtD
Leflunomide—Rash—Etoposide—sarcoma	0.000152	0.000645	CcSEcCtD
Leflunomide—Dermatitis—Etoposide—sarcoma	0.000152	0.000644	CcSEcCtD
Leflunomide—Headache—Etoposide—sarcoma	0.000151	0.000641	CcSEcCtD
Leflunomide—Flatulence—Doxorubicin—sarcoma	0.000151	0.00064	CcSEcCtD
Leflunomide—Dysgeusia—Doxorubicin—sarcoma	0.00015	0.000636	CcSEcCtD
Leflunomide—Malaise—Epirubicin—sarcoma	0.00015	0.000633	CcSEcCtD
Leflunomide—Vertigo—Epirubicin—sarcoma	0.000149	0.000631	CcSEcCtD
Leflunomide—Leukopenia—Epirubicin—sarcoma	0.000148	0.000629	CcSEcCtD
Leflunomide—Back pain—Doxorubicin—sarcoma	0.000148	0.000629	CcSEcCtD
Leflunomide—Muscle spasms—Doxorubicin—sarcoma	0.000148	0.000625	CcSEcCtD
Leflunomide—Palpitations—Epirubicin—sarcoma	0.000147	0.000621	CcSEcCtD
Leflunomide—CYP1A2—Tryptophan metabolism—MDM2—sarcoma	0.000146	0.00165	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—sarcoma	0.000146	0.00164	CbGpPWpGaD
Leflunomide—Cough—Epirubicin—sarcoma	0.000145	0.000613	CcSEcCtD
Leflunomide—Vision blurred—Doxorubicin—sarcoma	0.000145	0.000612	CcSEcCtD
Leflunomide—Nausea—Etoposide—sarcoma	0.000143	0.000607	CcSEcCtD
Leflunomide—Hypertension—Epirubicin—sarcoma	0.000143	0.000606	CcSEcCtD
Leflunomide—Ill-defined disorder—Doxorubicin—sarcoma	0.000142	0.000603	CcSEcCtD
Leflunomide—Anaemia—Doxorubicin—sarcoma	0.000142	0.000601	CcSEcCtD
Leflunomide—Myalgia—Epirubicin—sarcoma	0.000141	0.000598	CcSEcCtD
Leflunomide—Chest pain—Epirubicin—sarcoma	0.000141	0.000598	CcSEcCtD
Leflunomide—Arthralgia—Epirubicin—sarcoma	0.000141	0.000598	CcSEcCtD
Leflunomide—Anxiety—Epirubicin—sarcoma	0.000141	0.000596	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00014	0.000594	CcSEcCtD
Leflunomide—Discomfort—Epirubicin—sarcoma	0.000139	0.000591	CcSEcCtD
Leflunomide—Malaise—Doxorubicin—sarcoma	0.000138	0.000586	CcSEcCtD
Leflunomide—Dry mouth—Epirubicin—sarcoma	0.000138	0.000585	CcSEcCtD
Leflunomide—Vertigo—Doxorubicin—sarcoma	0.000138	0.000584	CcSEcCtD
Leflunomide—Leukopenia—Doxorubicin—sarcoma	0.000137	0.000582	CcSEcCtD
Leflunomide—Palpitations—Doxorubicin—sarcoma	0.000136	0.000574	CcSEcCtD
Leflunomide—Anaphylactic shock—Epirubicin—sarcoma	0.000135	0.000573	CcSEcCtD
Leflunomide—PTK2B—Immune System—PTPRC—sarcoma	0.000135	0.00152	CbGpPWpGaD
Leflunomide—Infection—Epirubicin—sarcoma	0.000134	0.000569	CcSEcCtD
Leflunomide—Cough—Doxorubicin—sarcoma	0.000134	0.000567	CcSEcCtD
Leflunomide—Nervous system disorder—Epirubicin—sarcoma	0.000133	0.000562	CcSEcCtD
Leflunomide—Thrombocytopenia—Epirubicin—sarcoma	0.000133	0.000561	CcSEcCtD
Leflunomide—Hypertension—Doxorubicin—sarcoma	0.000132	0.000561	CcSEcCtD
Leflunomide—Tachycardia—Epirubicin—sarcoma	0.000132	0.000559	CcSEcCtD
Leflunomide—PTK2B—Immune System—PLCG1—sarcoma	0.000132	0.00148	CbGpPWpGaD
Leflunomide—Skin disorder—Epirubicin—sarcoma	0.000131	0.000557	CcSEcCtD
Leflunomide—Hyperhidrosis—Epirubicin—sarcoma	0.000131	0.000554	CcSEcCtD
Leflunomide—Arthralgia—Doxorubicin—sarcoma	0.000131	0.000553	CcSEcCtD
Leflunomide—Myalgia—Doxorubicin—sarcoma	0.000131	0.000553	CcSEcCtD
Leflunomide—Chest pain—Doxorubicin—sarcoma	0.000131	0.000553	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	0.000131	0.00147	CbGpPWpGaD
Leflunomide—Anxiety—Doxorubicin—sarcoma	0.00013	0.000551	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.00013	0.000549	CcSEcCtD
Leflunomide—Discomfort—Doxorubicin—sarcoma	0.000129	0.000547	CcSEcCtD
Leflunomide—Anorexia—Epirubicin—sarcoma	0.000129	0.000546	CcSEcCtD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—NRAS—sarcoma	0.000129	0.00145	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TLE1—sarcoma	0.000128	0.00145	CbGpPWpGaD
Leflunomide—Dry mouth—Doxorubicin—sarcoma	0.000128	0.000541	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	0.000127	0.00143	CbGpPWpGaD
Leflunomide—Hypotension—Epirubicin—sarcoma	0.000126	0.000536	CcSEcCtD
Leflunomide—Anaphylactic shock—Doxorubicin—sarcoma	0.000125	0.00053	CcSEcCtD
Leflunomide—PTK2B—Immune System—ATF1—sarcoma	0.000125	0.00141	CbGpPWpGaD
Leflunomide—Infection—Doxorubicin—sarcoma	0.000124	0.000527	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000123	0.000522	CcSEcCtD
Leflunomide—Nervous system disorder—Doxorubicin—sarcoma	0.000123	0.00052	CcSEcCtD
Leflunomide—Thrombocytopenia—Doxorubicin—sarcoma	0.000123	0.000519	CcSEcCtD
Leflunomide—Insomnia—Epirubicin—sarcoma	0.000122	0.000518	CcSEcCtD
Leflunomide—Tachycardia—Doxorubicin—sarcoma	0.000122	0.000518	CcSEcCtD
Leflunomide—Skin disorder—Doxorubicin—sarcoma	0.000122	0.000515	CcSEcCtD
Leflunomide—Paraesthesia—Epirubicin—sarcoma	0.000122	0.000515	CcSEcCtD
Leflunomide—Hyperhidrosis—Doxorubicin—sarcoma	0.000121	0.000513	CcSEcCtD
Leflunomide—Dyspnoea—Epirubicin—sarcoma	0.000121	0.000511	CcSEcCtD
Leflunomide—Anorexia—Doxorubicin—sarcoma	0.000119	0.000505	CcSEcCtD
Leflunomide—Dyspepsia—Epirubicin—sarcoma	0.000119	0.000505	CcSEcCtD
Leflunomide—Decreased appetite—Epirubicin—sarcoma	0.000118	0.000498	CcSEcCtD
Leflunomide—Hypotension—Doxorubicin—sarcoma	0.000117	0.000496	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Epirubicin—sarcoma	0.000117	0.000495	CcSEcCtD
Leflunomide—Fatigue—Epirubicin—sarcoma	0.000117	0.000494	CcSEcCtD
Leflunomide—Constipation—Epirubicin—sarcoma	0.000116	0.00049	CcSEcCtD
Leflunomide—Pain—Epirubicin—sarcoma	0.000116	0.00049	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000114	0.000483	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000114	0.00128	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	0.000114	0.00128	CbGpPWpGaD
Leflunomide—Insomnia—Doxorubicin—sarcoma	0.000113	0.00048	CcSEcCtD
Leflunomide—Paraesthesia—Doxorubicin—sarcoma	0.000112	0.000476	CcSEcCtD
Leflunomide—Dyspnoea—Doxorubicin—sarcoma	0.000112	0.000473	CcSEcCtD
Leflunomide—Feeling abnormal—Epirubicin—sarcoma	0.000112	0.000472	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000111	0.00125	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—KRAS—sarcoma	0.000111	0.00125	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Epirubicin—sarcoma	0.000111	0.000469	CcSEcCtD
Leflunomide—Dyspepsia—Doxorubicin—sarcoma	0.00011	0.000467	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.00011	0.00123	CbGpPWpGaD
Leflunomide—Decreased appetite—Doxorubicin—sarcoma	0.000109	0.000461	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—VEGFC—sarcoma	0.000108	0.00122	CbGpPWpGaD
Leflunomide—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000108	0.000458	CcSEcCtD
Leflunomide—Fatigue—Doxorubicin—sarcoma	0.000108	0.000457	CcSEcCtD
Leflunomide—Urticaria—Epirubicin—sarcoma	0.000108	0.000455	CcSEcCtD
Leflunomide—Pain—Doxorubicin—sarcoma	0.000107	0.000453	CcSEcCtD
Leflunomide—Constipation—Doxorubicin—sarcoma	0.000107	0.000453	CcSEcCtD
Leflunomide—Body temperature increased—Epirubicin—sarcoma	0.000107	0.000453	CcSEcCtD
Leflunomide—Abdominal pain—Epirubicin—sarcoma	0.000107	0.000453	CcSEcCtD
Leflunomide—Feeling abnormal—Doxorubicin—sarcoma	0.000103	0.000437	CcSEcCtD
Leflunomide—Gastrointestinal pain—Doxorubicin—sarcoma	0.000102	0.000434	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000102	0.00115	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	9.98e-05	0.00112	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	9.98e-05	0.00112	CbGpPWpGaD
Leflunomide—Hypersensitivity—Epirubicin—sarcoma	9.97e-05	0.000422	CcSEcCtD
Leflunomide—Urticaria—Doxorubicin—sarcoma	9.95e-05	0.000421	CcSEcCtD
Leflunomide—Body temperature increased—Doxorubicin—sarcoma	9.9e-05	0.000419	CcSEcCtD
Leflunomide—Abdominal pain—Doxorubicin—sarcoma	9.9e-05	0.000419	CcSEcCtD
Leflunomide—Asthenia—Epirubicin—sarcoma	9.71e-05	0.000411	CcSEcCtD
Leflunomide—Pruritus—Epirubicin—sarcoma	9.57e-05	0.000405	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	9.43e-05	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—sarcoma	9.42e-05	0.00106	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—FOXO1—sarcoma	9.34e-05	0.00105	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—PDGFRB—sarcoma	9.33e-05	0.00105	CbGpPWpGaD
Leflunomide—Diarrhoea—Epirubicin—sarcoma	9.26e-05	0.000392	CcSEcCtD
Leflunomide—Hypersensitivity—Doxorubicin—sarcoma	9.23e-05	0.000391	CcSEcCtD
Leflunomide—PTK2B—Immune System—PDGFRA—sarcoma	9.18e-05	0.00103	CbGpPWpGaD
Leflunomide—Asthenia—Doxorubicin—sarcoma	8.98e-05	0.00038	CcSEcCtD
Leflunomide—Dizziness—Epirubicin—sarcoma	8.95e-05	0.000379	CcSEcCtD
Leflunomide—Pruritus—Doxorubicin—sarcoma	8.86e-05	0.000375	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—FLT1—sarcoma	8.66e-05	0.000975	CbGpPWpGaD
Leflunomide—Vomiting—Epirubicin—sarcoma	8.6e-05	0.000364	CcSEcCtD
Leflunomide—Diarrhoea—Doxorubicin—sarcoma	8.57e-05	0.000363	CcSEcCtD
Leflunomide—Rash—Epirubicin—sarcoma	8.53e-05	0.000361	CcSEcCtD
Leflunomide—Dermatitis—Epirubicin—sarcoma	8.52e-05	0.000361	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—PLCG1—sarcoma	8.51e-05	0.000959	CbGpPWpGaD
Leflunomide—Headache—Epirubicin—sarcoma	8.48e-05	0.000359	CcSEcCtD
Leflunomide—Dizziness—Doxorubicin—sarcoma	8.28e-05	0.000351	CcSEcCtD
Leflunomide—PTK2B—Signaling Pathways—CXCR4—sarcoma	8.18e-05	0.000921	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ATF1—sarcoma	8.09e-05	0.000911	CbGpPWpGaD
Leflunomide—Nausea—Epirubicin—sarcoma	8.04e-05	0.00034	CcSEcCtD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	8.02e-05	0.000903	CbGpPWpGaD
Leflunomide—Vomiting—Doxorubicin—sarcoma	7.96e-05	0.000337	CcSEcCtD
Leflunomide—Rash—Doxorubicin—sarcoma	7.9e-05	0.000334	CcSEcCtD
Leflunomide—Dermatitis—Doxorubicin—sarcoma	7.89e-05	0.000334	CcSEcCtD
Leflunomide—Headache—Doxorubicin—sarcoma	7.84e-05	0.000332	CcSEcCtD
Leflunomide—Nausea—Doxorubicin—sarcoma	7.44e-05	0.000315	CcSEcCtD
Leflunomide—PTK2B—Immune System—KIT—sarcoma	7.12e-05	0.000802	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CREB1—sarcoma	6.78e-05	0.000763	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IGF1R—sarcoma	6.35e-05	0.000715	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—FOXO1—sarcoma	6.04e-05	0.00068	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PDGFRB—sarcoma	6.03e-05	0.000679	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PDGFRA—sarcoma	5.94e-05	0.000668	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MDM2—sarcoma	5.61e-05	0.000631	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ENO2—sarcoma	5.58e-05	0.000628	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—HBA1—sarcoma	5.54e-05	0.000624	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—IL2—sarcoma	5.01e-05	0.000564	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KDR—sarcoma	5e-05	0.000563	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—JUN—sarcoma	4.87e-05	0.000549	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CTNNB1—sarcoma	4.84e-05	0.000545	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PLCG1—sarcoma	4.73e-05	0.000533	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KIT—sarcoma	4.6e-05	0.000518	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CREB1—sarcoma	4.38e-05	0.000493	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—SRC—sarcoma	4.37e-05	0.000492	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—NRAS—sarcoma	4.21e-05	0.000474	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—sarcoma	3.83e-05	0.000431	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MDM2—sarcoma	3.62e-05	0.000408	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—KRAS—sarcoma	3.62e-05	0.000408	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—IL2—sarcoma	3.24e-05	0.000365	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—sarcoma	3.16e-05	0.000356	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—JUN—sarcoma	3.15e-05	0.000355	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CTNNB1—sarcoma	3.13e-05	0.000352	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—sarcoma	3.08e-05	0.000346	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SRC—sarcoma	2.83e-05	0.000318	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ENO2—sarcoma	2.82e-05	0.000317	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—HBA1—sarcoma	2.8e-05	0.000315	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—VEGFA—sarcoma	2.75e-05	0.00031	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—NRAS—sarcoma	2.72e-05	0.000306	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—sarcoma	2.53e-05	0.000285	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—sarcoma	2.48e-05	0.000279	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ENO2—sarcoma	2.41e-05	0.000271	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—HBA1—sarcoma	2.39e-05	0.000269	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PLCG1—sarcoma	2.39e-05	0.000269	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—KRAS—sarcoma	2.34e-05	0.000263	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—sarcoma	2.08e-05	0.000234	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PLCG1—sarcoma	2.04e-05	0.00023	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—sarcoma	1.99e-05	0.000224	CbGpPWpGaD
